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Abstract
Tumour budding predicts survival of stage II colorectal cancer (CRC) and has been suggested to be associated
with epithelial-to-mesenchymal transition (EMT). However, the underlying molecular changes of tumour budding
remain poorly understood. Here, we performed multiplex immunohistochemistry (mIHC) to phenotypically profile
tumours using known EMT-associated markers: E-cadherin (adherence junctions), integrin β4 (ITGB4; basement
membrane), ZO-1 (tight junctions), and pan-cytokeratin. A subpopulation of patients showed high ITGB4 expres-
sion in tumour buds, and this coincided with a switch of ITGB4 localisation from the basal membrane of intact
epithelium to the cytoplasm of budding cells. Digital image analysis demonstrated that tumour budding with
high ITGB4 expression in tissue microarray (TMA) cores correlated with tumour budding assessed from haematox-
ylin and eosin (H&E) whole sections and independently predicted poor disease-specific survival in two indepen-
dent stage II CRC cohorts (hazard ratio [HR] = 4.50 (95% confidence interval [CI] = 1.50–13.5), n = 232;
HR = 3.52 (95% CI = 1.30–9.53), n = 72). Furthermore, digitally obtained ITGB4-high bud count in random
TMA cores was better associated with survival outcome than visual tumour bud count in corresponding H&E-
stained samples. In summary, the mIHC-based phenotypic profiling of human tumour tissue shows strong poten-
tial for the molecular characterisation of tumour biology and for the discovery of novel prognostic biomarkers.
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Introduction
The management of stage II colorectal cancer (CRC)
remains a major challenge as the currently used clinical
factors and prognostic biomarkers do not provide suffi-
cient information for risk assessment and therapy stratifi-
cation. Tumour budding has been shown to
independently predict the survival of stage II CRC
patients [1,2] and could potentially be used as a marker
for selecting high-risk stage II CRC patients for adjuvant
chemotherapy. Tumour budding is defined as single cells
or cell clusters of up to four or five cells at the invasive
margin of colorectal cancer [3–5]. It has also been shown
to associate with KRAS (G12D) [6,7] and BRAF [8]
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mutations and mismatch repair-proficient disease [9,10],
as well as lymphovascular invasion [5]. Visual evalua-
tion of haematoxylin and eosin (H&E) stains is the stan-
dard method for the assessment of tumour budding, a
method subject to inter- and intra-observer variation
[3,11]. Some studies have suggested improved accuracy
by applying cytokeratin immunohistochemistry (IHC) in
the assessment of tumour budding in CRC [11–15].
Tumour budding is also linked to epithelial-to-
mesenchymal transition (EMT), as evidenced by
decreased or aberrant expression of E-cadherin [16,17].
However, the molecular mechanisms and biology driv-
ing the high-grade budding in CRC are still poorly
defined. Thus, molecular characterisation and phenotypic
classification of tumour budding with association to
patient outcome prediction would be highly valuable.
The β4 integrin (ITGB4) subunit was initially
termed as a tumour-associated antigen (TSP180) asso-
ciated with metastasis [18,19]. The ITGB4 subunit
binds exclusively to the α6 integrin subunit, forming a
heterodimer of α6β4 integrin [20]. This heterodimer is
a receptor for laminin-5 (laminin-322) and mediates
the formation of adhesive structures called hemides-
mosomes on the epithelium basal surface [21]. In
CRC, the expression of ITGB4 has been shown to be
stronger in less differentiated areas, with isolated clus-
ters of tumour cells at the tumour–stroma interface
compared to well-differentiated carcinomas with a
cohesive growth pattern [22]. In a recent study, higher
expression of ITGB4 (74% of total of 68 patients) was
shown to stratify CRC patients into a higher-risk group
(overall survival [OS]) [23]. Furthermore, a ligand for
α6β4 integrin, laminin-5 γ2 subunit, is strongly
expressed at the invasive front and associates with
tumour budding and poor survival in pT3 CRC [24].
Altogether, these studies suggest that ITGB4 could
associate with tumour budding in CRC, but this has
not been addressed before.
Here, we have used multiplex IHC (mIHC) [25] and
automated digital image analysis to quantitatively ana-
lyse not only ITGB4 expression but also the expres-
sion of E-cadherin, ZO-1, and pan-cytokeratin
(PanCk) in total epithelial clusters and in smaller
tumour clusters representing a promising surrogate
marker for routine histologically analysed tumour bud-
ding in stage II CRC. The results demonstrate that the
number of tumour buds with high expression of
ITGB4 correlates with the visual assessment of tumour
budding from H&E whole sections, and it indepen-
dently predicts the survival of stage II CRC patients.
The power of fluorescence mIHC and high-content
quantitative image analysis is demonstrated by the
detailed molecular analysis of tumour budding.
Materials and methods
This study was implemented according to the REMARK
guidelines for reporting biomarker studies [26].
Study population
Discovery cohort
Archived paraffin-embedded tumour tissue was collected
from 232 consecutive stage II CRC patients operated on
at Turku University Hospital from 2005 to 2012. The
collection of clinical patient data was approved by the
administration of Turku University Hospital, Hospital
District of Southwest Finland (T52/2014). The use of tis-
sue material was approved by the Scientific Steering
Group of Auria Biobank (AB15-8108, 25 May 2012) as
well as the National Authority for Medico-Legal affairs
(Dnro 4423/32/300/02). The study was conducted in
accordance with the Declaration of Helsinki. Only
patients with stage II CRC were included in the current
study. For tumour staging, TNM7 classification of
malignant tumours was used [27]. The patient character-
istics are given in Table 1.
Validation cohort
The cohort consisted of 72 consecutive stage II
(Dukes B) CRC patients operated between 1998 and
2000 at the Department of Surgery, Helsinki Univer-
sity Hospital. Archived formalin-fixed and paraffin-
embedded tumour samples were collected from the
archives of the Department of Pathology, Helsinki
University Central Hospital. The Finnish Population
Register Centre provided follow-up vital status data,
and Statistics Finland provided cause of death for
those deceased. This cohort study was approved by
the local Ethics Committee (Dnro HUS 226/E6/06,
extension TMK02 §66 17.4.2013) and the National
Supervisory Authority of Welfare and Health (Valvira
Dnro 10041/06.01.03.01/2012).
Tissue microarrays
Tissue microarrays (TMA) of the discovery cohort
were constructed and analysed using the next-
generation TMA technique [28] as described in Slik
et al 2017 [29]. The validation TMA construction has
been described earlier in [30].
Visual scoring of H&E tumour budding
Tumour budding was analysed as previously recom-
mended by the International Tumour Budding Consen-
sus Conference (ITBCC) 2016 [3]. The invasive front
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was screened with a ×10 objective in order to find the
‘hot-spot’ area. The tumour buds in the selected ‘hot-
spot’ area were counted using a ×20 objective. The
bud counts were divided by the normalisation factor to
adjust the tumour bud count per 0.785 mm2. Tumour
budding was scored blinded to clinical data indepen-
dently by two pathologists (KS and JS). A consensus
was formed from discrepant results, leading to differ-
ent budding categories. For visual tumour budding,
220 patients with evaluable high-quality tissue cores
were scored.
Multiplex immunohistochemistry and imaging
The mIHC was carried out as described in Blom et al
(2017) [25]. The method is based on secondary anti-
body detection of fluorescent labels. Five-channel fluo-
rescent images were acquired using the Metafer
5 scanning and imaging platform (MetaSystems, Ger-
many), applying a ×20 objective (NA 0.8). Further
details can be found in the supplementary material,
Supplementary materials and methods.
Image analysis pipeline
For image analysis, exported TIFF images were down-
scaled to 1:4 from the original resolution (final resolu-
tion 0.88 μm/pixel). The image analysis was carried
out using cell image analysis software (CellProfiler
version 2.2.0 [31]). The pipeline consisted of four
major steps: (1) spot detection, (2) epithelial cluster
and bud detection, (3) measurement of channel intensi-
ties, and (4) data export. Further details are given in
the supplementary material, Supplementary materials
and methods.
Statistics
For the association analysis of variables, the two-sided
χ2 association test (Chi-square) or Fisher’s exact test
was used. Normality of the data was tested using the
Kolmogorov–Smirnov test. Correlations were calcu-
lated using the non-parametric two-tailed Spearman
rho test. P values for mean and median comparisons
were calculated using either the Student’s t-test
(normal distribution) or the Mann–Whitney U test
(non-normal distribution). Correlation and association
analyses were performed using IBM SPSS 24 (SPSS
Inc., Armonk, NY, USA). The Cox proportional haz-
ard regression model and Kaplan–Meier analysis with
log-rank test for survival analysis were performed
using R version 3.4.3 (Foundation for Statistical
Computing, Vienna, Austria) and RStudio 1.1.383
(RStudio Inc. Boston, MA, USA) with survival
Table 1. Patient characteristics. Stage II CRC discovery cohort
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package 2.41-3. Proportional hazard assumption was
tested for each variable using the Schoenfeld test. The
P values in Cox regression analysis were calculated
using a Wald test.
Results
Visually assessed tumour budding is predictive for
survival end-points
Tumour budding predicts survival of stage II CRC [3].
To validate our stage II cohort of 232 patients in this
regard, we performed scoring of H&E sections for
tumour budding according to the guidelines set by the
ITBCC [3]. In brief, a ‘hot-spot’ region, obtained with
×20 objective and adjusted to represent an area of
0.785 mm2 (equivalent to approximately one ×20 field
of view) in the tumour front region of a whole section,
was selected for manual counting. A three-tier scoring
system was used in the following manner: Bd 1 = 0–4
buds, Bd 2 = 5–9 buds, Bd 3 = ≥ 10 buds. Using the
three-tier scoring, 84.8% of patients (n=220) scored as
Bd 1, 7.8% as Bd 2, and 7.4% as Bd 3.
Univariate Cox regression and Kaplan–Meier plots
demonstrated a significantly shorter disease-specific
survival (DSS) for the Bd 2 (hazard ratio [HR] = 6.95;
95% confidence interval [CI] = 2.64–18.28) and Bd
3 (HR = 5.55; 95% CI = 2.00–15.44) patient groups
compared to the Bd 1 group (Figure 1A). As the Bd
2 and Bd 3 patient groups showed similar risk, we also
dichotomised the cohort using optimal separation cut-
off values with seven or more buds in the high-grade
budding group (HR = 7.55; 95% CI = 2.64–18.28)
(Figure 1B). Disease-free survival (DFS) and OS were
also analysed as end-points, showing similar results
(see supplementary material, Figure S1A,B).
When adjusted for different clinicopathological vari-
ables in a multivariate Cox regression analysis, the Bd
2 score, but not the Bd 3 score, independently strati-
fied patients to higher risk (DSS) compared to the Bd
1 score (Table 2). However, using the two-tiered scor-
ing system, high-grade tumour budding (≥7 buds) was
an independent predictor of poor DSS (see supplemen-
tary material, Table S1). Of the other variables, tumour
pT status (pT4 versus pT3) and vascular invasion were
also independent prognostic factors (HR = 4.12; 95%
CI = 1.53–11.14 and HR = 3.27; 95% CI = 1.20–8.94,
respectively). Tumour budding was significantly asso-
ciated with tumour perforation (χ2, p < 0.001) and pre-
operative obstruction (χ2, p < 0.001) in this patient
series (see supplementary material, Table S2). There-
fore, we conclude that tumour budding is associated
with adverse pathology and predicts survival in this
patient cohort, and this demonstrates that the cohort is
applicable for phenotypic profiling of tumour budding
biology.
ITGB4 is diffusely expressed in cells resembling
tumour budding cells
To study molecular and morphological changes associ-
ated with tumour budding both in the peritumoural
and intratumoural areas, we analysed a TMA consist-
ing of one to two normal epithelium (tumour adja-
cent), two tumour centres, and two tumour front cores
representing the corresponding patient sample blocks
that were used for H&E tumour budding scoring
(Figure 2A). As tumour budding has been suggested
Figure 1. Survival analysis of tumour budding from H&E-stained whole sections assessed by visual scoring according to ITBCC (2016)
guidelines. (A) Three-tier Kaplan–Meier (log-rank) plots for DSS, where Bd 1 = 0–4 buds (84.8%), Bd 2 = 5–9 buds (7.8%), and Bd
3 ≥ 10 buds (7.4% of patients). The values in brackets indicate the number of events/patients. (B) Dichotomisation of patients for low
and high budding groups using optimal separation (high group ≥7 buds; 11% of patients). Cox univariate regression analysis; **p < 0.01;
***p < 0.001. Ref, reference.
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Table 2. Univariate and multivariate Cox regression analysis (DSS) of visually assessed tumour budding (three-tier) and of the
clinicopathological variables used
Variable Univariate HR (95% CI) P value Multivariate HR (95% CI) (n = 195) P value
Tumour budding H&E
Bd 1 (n = 192) 1 (ref) 1 (ref)
Bd 2 (n = 24) 6.95 (2.64–18.28) 8.48E−05 5.63 (1.63–19.39) 0.0062
Bd 3 (n = 16) 5.55 (2.00–15.44) 0.0010 3.13 (0.91–10.70) 0.069
n.d. = 12
Age
≤70 (n = 85) 1 (ref) 1 (ref)
>70 (n = 135) 0.82 (0.39–1.75) 0.6143 1.43 (0.48–4.26) 0.5216
n.d. = 12
Gender
Female (n = 113) 1 (ref) 1 (ref)
Male (n = 107) 0.89 (0.42–1.91) 0.7669 1.61 (0.61–4.28) 0.3359
n.d. = 12
Tumour side
Right side (n = 108) 1 (ref) 1 (ref)
Left side (112) 1.42 (0.66–3.05) 0.3754 1.18 (0.45–3.11) 0.7423
n.d. = 12
pT-status
T3N0 (n = 178) 1 (ref) 1 (ref)
T4abN0 (n = 42) 3.02 (1.38–6.62) 0.006 4.38 (1.54–12.46) 0.0056
Grade
G1–2 (n = 169) 1 (ref) 1 (ref)
G3 (n = 50) 1.00 (0.40–2.47) 0.9939 0.76 (0.25–2.29) 0.6197
n.d. = 13
Histology
Conventional (n = 193) 1 (ref) n.d.
Mucinous (n = 26) 0.69 (0.16–2.91) 0.6104 n.d.
n.d. = 13
Preop. obstruction
No (n = 186) 1 (ref) 1 (ref)
Yes (n = 34) 1.58 (0.64–3.91) 0.3268 0.71 (0.21–2.34) 0.5707
n.d. = 12
Perforation
No (n = 203) 1 (ref) 1 (ref)
Yes (n = 18) 4.39 (1.76–10.95) 0.0015 4.04 (1.18–13.82) 0.0259
n.d. = 12
Radicality
R0 (n = 203) 1 (ref) n.d.
R1 (n = 14) 0.59 (0.08–4.37) 0.606 n.d.
R2 (n = 3) 15.71 (3.61–68.35) 0.0002 n.d.
n.d. = 12
LN count
≥12 LNs (n = 175) 1 (ref) n.d.
<12 LNs (n = 45) 1.57 (0.69–3.60) 0.285 n.d.
n.d. = 12
Vascular invasion
No (n = 171) 1 (ref) 1 (ref)
Yes (n = 37) 2.10 (0.92–4.80) 0.0789 3.57 (1.33–9.55) 0.0114
n.d. = 12
Adj. chemotherapy
No (155) 1 (ref) 1 (ref)
Yes (64) 1.57 (0.73–3.38) 0.2519 1.18 (0.35–4.01) 0.7877
n.d. = 13
MSI status
MSS (n = 170) 1 (ref) 1 (ref)
MSI high (n = 42) 0.52 (0.16–1.75) 0.2927 0.70 (0.12–4.12) 0.6919
n.d. = 20
(Continued)
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to be associated with EMT, where typically adherens
junctions (marker: E-cadherin), tight junctions
(marker: ZO-1), and basal membranes (marker:
ITGB4) are dissociated [32], we used mIHC [25] to
detect these markers simultaneously. In addition, we
included PanCk antibodies and DAPI to mark the epi-
thelial cells and nuclei, respectively. We hypothesised
that mIHC and automated digital image analysis would
allow the discovery of novel phenotypes not indicated
by single-marker IHC.
We observed a typical staining pattern of ZO-1 in the
apical cell junctions and of ITGB4 in the basal cell–cell
contacts and basal membrane in normal epithelium, as
well as in well-differentiated carcinoma epithelium from
tumour centre cores (Figure 2B). However, changes in
staining pattern were noted in less-differentiated tumour
front areas of invasive-looking budding cells (Figure 2B,
right panel, and Figure 2C,D). More specifically, we
observed that, in a subset of tumours, the expression of
ITGB4 was strong in tumour budding cells and that this
coincided with a localisation switch of ITGB4 from
basal membrane and cell–cell contacts of intact epithe-
lium to diffusively fill the cytoplasm of the budding
tumour cells (Figure 2C). However, clear inter-tumoural
heterogeneity was noted (Figure 2D).
Quantification of epithelial clusters, buds, and buds
with high ITGB4 expression
To systematically analyse the nature of tumour bud-
ding, we set up an automated digital image analysis
pipeline to enable the quantification of the marker
intensities and the grade of tumour budding in more
than 1000 TMA spots (230 patients). First, we
observed that neither of the widely used PanCk anti-
body clones (C-11 and AE1/3) alone fully covered
epithelial cells in colorectal samples, but a combina-
tion of the two clones showed a better coverage (see
supplementary material, Figure S2). For optimal epi-
thelial cluster segmentation, we combined signals from
three different fluorescence channels: PanCk (Tyr-
Alexa-488), ITGB4 (Alexa-647), and E-Cadherin
(Alexa-750) (see supplementary material, Figure S3A–
C). In the image analysis, we first identified epithelial
clusters as objects using a set threshold for PanCk, E-
cadherin and ITGB4 positivity (Figure 3A and
Section 2). Digital buds were defined as epithelial clus-
ters with area 35–1000 pixels, visually matching the bud
size in H&E images. ITGB4-high buds were defined as
buds with ITGB4 expression higher than median inten-
sity in all epithelial clusters in the full cohort (cut-off
value for ITGB4 high expression = 26 units; Figure 3A,
B). The average count of total buds and ITGB4-high
buds in the tumour front cores were 27 and 11, respec-
tively, much higher than the average bud count in the
visual H&E analysis (average = 3). Nuclei analysis in an
example high-grade budding spot demonstrated that
98% of total buds and 96% of ITGB4-high buds had 0–4
nuclei (see supplementary material, Figure S4) and that
nuclei were more often absent in total buds than in
ITGB4-high buds (61% versus 31%).
Analysis of the marker intensities across all the epi-
thelial clusters (n = 43 414) demonstrated that the
expression levels of E-cadherin, ITGB4, and ZO-1
were the highest in normal epithelium clusters, lower
in tumour centre, and lowest in tumour front clusters
(Figure 3B). In contrast, the expression of PanCk
increased significantly from normal epithelium to
tumour centre and from tumour centre to tumour front
clusters. Importantly, ITGB4 levels showed a high
degree of variation, especially in tumour centre and in
tumour front, where high-intensity ‘outlier’ clusters
were found, reflecting the heterogeneity of ITGB4
expression observed earlier in the different tumour
budding phenotypes (see Figure 2C,D). Importantly,
the epithelial marker expression profiles were different
in epithelial clusters and buds, indicated by signifi-
cantly lower expression of E-cadherin, ITGB4, and
ZO-1, but higher expression of PanCk in buds com-
pared to non-bud epithelial clusters of the tumour
Table 2. Continued
Variable Univariate HR (95% CI) P value Multivariate HR (95% CI) (n = 195) P value
BRAF status
WT (n = 181) 1 (ref) 1 (ref)
V600E (n = 28) 0.61 (0.14–2.61) 0.5067 1.31 (0.15–11.87) 0.8126
n.d. = 21
Ezrin
Low (n = 98) 1 (ref) n.d.
Intermediate (n = 36) 1.39 (0.42–4.62) 0.5895 n.d.
High (n = 38) 3.19 (1.19–8.54) 0.0209 n.d.
n.d. = 48
LN, lymph node. Underlined numbers highlight significance compared to a reference value (ref) as measured by Wald test (p < 0.05).
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Figure 2. mIHC staining for epithelial markers using a multi-focal TMA demonstrates heterogeneity of ITGB4 expression.
(A) Representative areas of tumour-adjacent normal epithelium (benign), tumour centre, and tumour front were visually determined
using H&E-stained whole-tissue sections, and 1.2-mm punch cores were used to construct a TMA cohort of 232 patients. The TMA
cohort sections were stained for simultaneous detection of PanCk (cytokeratins), ZO-1 (apical tight junctions), ITGB4 (basal membrane),
E-cadherin (ECADH, adherens junctions), and DAPI (nuclei). High-resolution five-channel scanning (0.22 μm/pixel) was performed prior
to visual observation and automated digital image analysis of the multiplex images. Scale bar = 2 mm. (B) Example images of tissue
cores of normal (left), centre (middle), and front (right) areas of CRC samples, respectively. Scale bar = 200 μm. (C,D) Heterogeneity of
ITGB4 expression: strong cytoplasmic ITGB4 (red) expression in invasive cell buds (C) and weak ITGB4 expression in cell buds (D). White
arrowed lines and their corresponding intensity plots for E-cadherin (ECADH, green) and ITGB4 (red) as measured along the line pixels to
the direction of the arrow (intensity scale = 0–255) are shown as insets. Scale bar = 40 μm.
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samples (Figure 3C). As expected, the bud counts
were higher in tumour than in normal epithelium cores
and were higher in tumour front cores than in tumour
centre cores (Figure 3D).
Analysis of tight junction perimeter (see supplemen-
tary material, Supplementary materials and methods;
Figure S3D for details) in epithelial clusters showed
that the mean perimeter was the largest in the normal
epithelium TMA spots and smallest in the tumour
front spots, reflecting the disintegration level of the
epithelial clusters (Figure 3E). Interestingly, the perim-
eter inversely correlated with the number of
ITGB4-high buds when measured across all the TMA
cores (n = 1093) (see supplementary material,
Figure S3E). Similarly, the median intensity of E-
cadherin in epithelial clusters was inversely correlated
with the number of ITGB4-high buds (see supplemen-
tary material, Figure S3E). Co-localisation analysis
(per pixel Rank-weighted co-localisation) of the
epithelial markers demonstrated that ITGB4 and E-
cadherin had a high median co-localisation coefficient
(0.64) in non-bud epithelial clusters, whereas in digital
buds, this value was zero (Figure 3F). By contrast, the
basally expressed ITGB4 and apically expressed ZO1
had almost absent co-localisation in any epithelial
objects (coefficient_nonbuds = 0.02; buds = 0).
To study how digitally analysed bud counts reflect
visually assessed tumour budding, we correlated digi-
tal bud counts of tumour front TMA cores against
pathologist’s visual scoring of whole H&E sections
and of H&E TMA sections across all patients. In addi-
tion, we also included in this analysis visually assessed
budding scores from samples stained only with PanCk.
When comparing total digital tumour budding with
ITGB4-high tumour budding, ITGB4-high budding
correlated better with visual tumour budding assessed
in either whole-section H&E samples, in H&E TMA
samples, or in cytokeratin-stained samples (Table 3).
Table 3. Correlations of visually and digitally assessed tumour budding variables
Visual analysis Digital analysis
Spearman’s rho HE_WS_VIA HE_TMA_VIA CK_TMA_VIA TB_DIA ITGB4-high TB DIA
HE_WS_VIA Corr coef. 1 0.303 0.408 0.218 0.352
P value 6.8E−06 1.1E−09 0.001 1.0E−07
n 220 212 206 216 216
HE_TMA_VIA Corr coef. 0.303 1 0.321 0.175 0.326
P value 6.8E−06 2.0E−06 0.010 1.0 E−06
n 212 212 206 212 212
CK_TMA_VIA Corr coef. 0.408 0.321 1 0.488 0.659
P value 1.1E−09 2.6 E−06 1.0E−13 4.9E−27
n 206 206 206 206 206
TB_DIA Corr coef. 0.218 0.175 0.488 1 0.716
P value 0.001 0.010 1.0E−13 2.9E−35
n 216 212 206 216 216
ITGB4-high TB DIA Corr coef. 0.352 0.326 0.659 0.716 1
P value 1.0E−07 1.2E−06 4.9E−27 2.9E−35
n 216 212 206 216 216
The table shows correlations using continuous, non-categorised budding counts. The values for HE_TMA_VIA and CK_TMA_VIA as well as digital analysis represent
TMA tumour front.
HE_WS_VIA, H&E whole-section visual analysis; HE_TMA_VIA, H&E TMA visual analysis; CK_TMA_VIA, cytokeratin TMA visual analysis; TB_DIA, tumour budding
digital analysis; ITGB4_TB_DIA, ITGB4-high tumour budding digital analysis. Underlined type = p ≤ 0.01 (two-tailed, non-parametric).
Figure 3. Automated digital image analysis for the segmentation of epithelial areas (clusters), buds, and ITGB4-high buds. (A) A scheme
of the epithelial segmentation using combined channels of PanCk, E-cadherin (ECADH), and ITGB4. CellProfiler software was used for the
automated detection of epithelial clusters and buds (clusters of 1–5 cells). ITGB4-high buds were defined as buds with high ITGB4 expres-
sion (cut-off = median ITGB4 across all the clusters; 26 intensity units; Scale = 0–255). See image analysis details in Section 2. The rect-
angles indicate blow-up regions shown in the lower panels. Scale bar = 200 μm. (B) Channel intensities across all the epithelial clusters
within normal epithelium (Normal Epi) (B) (n = 6774), tumour centre (C) (n = 17 272), and tumour front (F) cores (n = 19 369). Scale
bar = 400 μm. (C) Median channel intensities within buds (n = 29 227) and non-buds (n = 7985) of tumour cores. (D) Mean counts of
buds and ITGB4-high buds within different cores of the TMA cohort. (E) Median tight junction (TJ) perimeter in pixels within normal and
tumour cores. (F) Rank-weighted co-localisation (RWC) analysis of epithelial markers within epithelial non-buds and buds. The markers’
pixel-based localisations and their intensities were compared pairwise using CellProfiler. The error bars represent standard deviation
except in D, where standard error of the mean was used. *p < 0.05; **p < 0.01; ***p < 0.001 (non-parametric Mann–Whitney U test).
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ITGB4-high bud count is an independent predictor
of survival
To investigate the potential prognostic relevance of
digitally assessed tumour budding, we performed sur-
vival analysis for digital total bud counts and for digi-
tal ITGB4-high bud counts in the stage II TMA
cohort. In comparison, the visually assessed tumour
budding scores were also analysed for survival effects.
As the digitally assessed bud counts were much higher
than in the whole-section H&E visual analysis, the
same cut-off values for absolute bud counts could not
be used. Instead, we used two-tier scoring with
optimal cut-off separation (DSS outcome) for each
budding analysis (Table 4). The results demonstrate
that the whole-section ‘hot-spot’ H&E tumour bud
scoring is the best predictor of disease outcome.
Importantly, however, the ITGB4-high bud count in
TMA cores is better associated with survival status
than the bud counts visually assessed from H&E-
stained or PanCk-stained TMA samples (Table 4).
Importantly, using the optimal dichotomisation, the
ITGB4-high bud score (≥25 buds) was also an inde-
pendent predictor of DSS in a multivariate analysis
(Table 5) (HR = 4.50; 95% CI = 1.50–13.5). In con-
trast, the total bud count (without high ITGB4)
(Table 4) or average expression intensity of ITGB4 in
the epithelial clusters or in buds was not predictive for
outcomes (see supplementary material, Table S3).
To validate the prognostic power of ITGB4-high
budding in an independent CRC cohort, we performed
mIHC staining, scanning, and image analysis as with
the discovery cohort, but now using a stage II valida-
tion cohort of 72 patients (see supplementary material,
Table S4 for clinicopathological variables). For sur-
vival analysis, we used the same bud count cut-off
values for patient stratifications as were used in the
discovery cohort digital analysis. Importantly, in the
validation cohort, the ITGB4-high bud count (≥25
buds) also predicted DSS (HR = 3.61; 95%
CI = 1.34–9.74) and was independent of age, gender,
tumour side, and tumour grade (see supplementary
material, Table S5; HR = 3.52; 95% CI = 1.30–9.53).
Similar to the discovery cohort, the total bud count
was not predictive for DSS (HR = 1.88; 95%
CI = 0.65–5.42). The results demonstrate that, even
though the expression of ITGB4 alone is not prognos-
tic, and although ITGB4 expression is downregulated
in buds in general, patients with a high expression of
ITGB4 in high-grade tumour budding cells have a sig-
nificantly increased risk of cancer-specific death in
stage II CRC. Furthermore, the results show that the
high-content digital analysis of multiple epithelial
markers enabled the investigation of budding pheno-
types and discovery of the association of ITGB4
expression with tumour budding in ‘cold-spot’ samples
of the tumour front.
Table 4. Association of digitally and visually assessed bud counts with clinicopathological variables
Variable HE_WS_VIA HE_TMA_VIA CK_TMA_VIA TB_DIA ITGB4_TB_DIA
High bud cut-off ≥7 (11%) ≥2 (10%) ≥28 (8%) ≥34 (23%) ≥25 (9%)
Age 0.486 0.503 0.32 0.445 0.352
Gender 0.281 0.149 0.368 0.216 0.347
Tumour side 0.466 0.443 0.468 0.153 0.449
pT-status 0.183 0.478 0.453 0.403 0.54
Grade 0.379 0.134 0.578 0.117 0.56
Histology 0.517 0.072 0.481 0.485 0.619
Preop. obstruction 1.80E−04 5.20E−05 0.002 0.217 0.037
Perforation 3.00E−06 0.013 0.115 0.004 0.01
Radicality 0.189 0.586 0.88 0.428 0.181
Ln count 0.275 0.411 0.365 0.523 0.164
Vascular invasion 0.341 0.253 0.545 0.43 0.605
Adj. chemotherapy 0.11 0.526 0.443 0.329 0.483
MSI status 0.311 0.556 0.335 0.514 0.159
BRAF status 0.173 0.494 0.608 0.633 0.441
DSS status 3.7E−05 0.097 0.039 0.079 0.002
DFS status 0.01 0.162 0.184 0.178 0.027
HR (DSS) 7.55 3.01 2.98 2.13 5.09
95% CI (DSS) 2.64–18.28 1.13–8.04 1.12–7.94 0.94–4.83 2.12–12.2
Budding counts were dichotomised using optimal cut-off values for each parameter using DSS as end-point. The values (except HR and 95% CI) represent P values
of Fisher's exact test. HR = univariate Hazard ratio (Cox regression).
HE_WS_VIA, H&E whole-section visual analysis; HE_TMA_VIA, H&E TMA visual analysis; CK_TMA_VIA, cytokeratin TMA visual analysis; TB_DIA, tumour budding
digital analysis; ITGB4_TB_DIA, ITGB4-high tumour budding digital analysis; LN, lymph node. Underlined type = p < 0.05.
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Table 5. Univariate and multivariate Cox regression analysis (DSS) for ITGB4-high bud count using two-tier patient grouping in stage II
TMA cohort
Variable
Univariate HR (95% CI) Multivariate HR (95% CI)
n = 232 P value n = 195 P value
ITGB4-high buds
Low (n = 197) 1 (ref) 1 (ref)
High (n = 19) 5.09 (2.12–12.22) 0.0003 4.50 (1.50–13.5) 0.007
n.d. = 16
Age
≤70 (n = 85) 1 (ref) 1 (ref)
>70 (n = 135) 0.82 (0.39–1.75) 0.6143 1.14 (0.37–3.50) 0.8127
n.d. = 12
Gender
Female (n = 113) 1 (ref) 1 (ref)
Male (n = 107) 0.89 (0.42–1.91) 0.7669 1.26 (0.50–3.16) 0.6264
n.d. = 12
Tumour side
Right side (n = 108) 1 (ref) 1 (ref)
Left side (112) 1.42 (0.66–3.05) 0.3754 1.24 (0.49–3.15) 0.5629
n.d. = 12
Stage
T3N0 (n = 178) 1 (ref) 1 (ref)
T4abN0 (n = 42) 3.02 (1.38–6.62) 0.006 5.61 (2.00–15.71) 0.001
Grade
G1–2 (n = 169) 1 (ref) 1 (ref)
G3 (n = 50) 1.00 (0.40–2.47) 0.9939 0.90 (0.28–2.89) 0.8567
n.d. = 13
Histology
Conventional (n = 193) 1 (ref) n.d.
Mucinous (n = 26) 0.69 (0.16–2.91) 0.6104 n.d.
n.d. = 13
Preop. obstruction
No (n = 186) 1 (ref) 1 (ref)
Yes (n = 34) 1.58 (0.64–3.91) 0.3268 1.01 (0.34–3.02) 0.9884
n.d. = 12
Perforation
No (n = 203) 1 (ref) 1 (ref)
Yes (n = 18) 4.39 (1.76–10.95) 0.0015 3.95 (1.21–12.90) 0.0227
n.d. = 12
Radicality
R0 (n = 203) 1 (ref) n.d.
R1 (n = 14) 0.59 (0.08–4.37) n.d.
R2 (n = 3) 15.71 (3.61–68.35) n.d.
n.d. = 12
Ln count
≥12 LNs (n = 175) 1 (ref) n.d.
<12 LNs (n = 45) 1.57 (0.69–3.60) n.d.
n.d. = 12
Vascular invasion
No (n = 171) 1 (ref) 1 (ref)
Yes (n = 37) 2.10 (0.92–4.80) 0.0789 3.02 (1.15–7.93) 0.0245
n.d. = 12
Adj. chemotherapy
No (155) 1 (ref) 1 (ref)
Yes (64) 1.57 (0.73–3.38) 0.2519 1.04 (0.29–3.70) 0.9514
n.d. = 13
MSI status
MSS (n = 170) 1 (ref) 1 (ref)
MSI high (n = 42) 0.52 (0.16–1.75) 0.2927 0.39 (0.08–1.89) 0.2404
n.d. = 20
(Continued)
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Discussion
Tumour budding has already been recognised as an
additional prognostic factor in the TNM-8 classifica-
tion of CRC [33]. Visual scoring of tumour budding is
prone to inter-observer variation due to the difficulty
of distinguishing between infiltrating immune cells or
stromal fibroblasts and scattered tumour cells and also
due to the fragmentation of epithelial tissue upon apo-
ptosis/necrosis [2]. IHC, and especially cytokeratin
staining, has been applied to aid in the visualisation
and scoring of tumour budding. The scope of this
study was to apply mIHC and automated digital analy-
sis to define epithelial areas (clusters) and digital buds
in order to enable the measurement of marker expres-
sion within different epithelial compartments. In the
analysis of tumour budding from small TMA cores,
we demonstrate that a combination of epithelial
markers, rather than a single marker or H&E alone,
may better reflect the visually assessed tumour bud-
ding in the corresponding whole H&E sections.
For the detection of epithelial cells, we discovered
that two different PanCk antibodies (AE1/3 and C-11),
when used alone, did not cover all the epithelial struc-
tures (see supplementary material, Figure S2) but that
a combination of the two resulted in better coverage.
As the cytokeratin family of proteins consists of 20 dif-
ferent basic and acidic subunits, which typically form
a variety of heterodimers, it is highly possible that
there is a large variation of subunit distribution across
different tumours, but also within the epithelium of the
same tumour.
For imaging in this study, we used fixed-light expo-
sure times for different channels, adaptive thresholds
(Otsu’s) for object detection, and fixed size filtering
for tumour bud detection both in the discovery and the
validation cohorts (see supplementary material,
Supplementary materials and methods for exact
details). It is obvious that the same metrics of imaging
and analysis cannot be used for replication studies
using different instruments or fluorescence reagents
but need to be optimised separately in each laboratory.
These technical variations bring about limitations in
applying fluorescence-based digital imaging in the
clinical pathology laboratory. However, we demon-
strate that the approach can be of great value in clini-
cal research.
In this study, we compared conventional visual scor-
ing of tumour budding in H&E-stained sections, with
bud scoring assessed by digital analysis. Our results
demonstrate that whole-section visual scoring of
tumour budding from hot-spot areas is superior to ran-
domly selected TMA cores. However, we also show
that the use of epithelial markers PanCk and ITGB4 to
identify small epithelial clusters greatly improves the
ability to predict survival even from these randomly
selected TMA spots compared to conventional tumour
budding analysis from H&E-stained TMA slides only.
This could be important in small biopsies from CRC,
which correspond to the situation with randomly cho-
sen TMA spots from tumour areas. The current guide-
lines recommend the analysis of tumour budding from
H&E-stained sections, but PanCk staining can be used
in challenging cases [3]. This recommendation is
derived from the fact that earlier outcome data for
tumour budding were largely based on using H&E-
analysed material only [3]. However, it is possible that
the significance of IHC-guided tumour budding will
lead to it having a more important role in the future. In
addition, in the current study, the marker combination
of ITGB4 and PanCk resulted in better correlations
with survival than PanCk alone. This may be related
to the fact that PanCk demonstrates all the epithelial
cell clusters (including necrotic fragments), whereas
ITGB4 is more specific for invasive cells (when
Table 5. Continued
Variable
Univariate HR (95% CI) Multivariate HR (95% CI)
n = 232 P value n = 195 P value
BRAF status
WT (n = 181) 1 (ref) 1 (ref)
V600E (n = 28) 0.61 (0.14–2.61) 0.5067 0.69 (0.10–4.89) 0.7071
n.d. = 21
Ezrin
Low (n = 98) 1 (ref) n.d.
Intermediate (n = 36) 1.39 (0.42–4.62) 0.58 n.d.
High (n = 38) 3.19 (1.19–8.54) 0.0209 n.d.
n.d. = 48
The dichotomisation of patients into low and high ITGB4 bud counts was based on optimal cut-off (high≥25 buds).
LN, lymph node. Underlined numbers highlight significance compared to a reference value (ref) as measured by Wald test (p < 0.05).
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present in small cell clusters) and is involved in EMT
[34], a phenomenon to which tumour budding is at
least partly related [4]. For this reason, it is tempting
to hypothesise that biomarkers linked with EMT,
which have also shown correlation with survival [35],
might be relevant additional markers of tumour bud-
ding in challenging tumour specimens.
EMT is a phenomenon consisting of loss or aberrant
expression of adherence junction E-cadherin, disinte-
gration of tight junctions (ZO-1), and of basement
membranes (ITGB4). These are typically associated
with elevated mesenchymal transcription factor expres-
sion and increased cell scattering/invasion [32]. In this
study, we digitally measured the expression of E-cad-
herin, ZO-1, and ITGB4 in more than 1000 TMA
cores and in more than 43 000 epithelial clusters. As a
result, we found lower levels of these markers in can-
cer cores compared with tumour-adjacent normal epi-
thelium cores. In addition, all three markers were
downregulated in tumour buds compared to non-bud
epithelial clusters. Moreover, the epithelial tight junc-
tion perimeter was significantly smaller when compar-
ing normal epithelium to cancer or tumour centre to
tumour border samples, reflecting tight junction disin-
tegration of the epithelium. Importantly, both the tight
junction perimeter and the E-cadherin expression cor-
related inversely with the number of ITGB4-high
buds, and the co-localisation of E-cadherin and ITGB4
was significantly lower in epithelial buds compared
with non-buds. Together, these results point out that
ITGB4-related budding links with several factors asso-
ciated with the structural disintegration of the epithe-
lium and thus suggest that ITGB4-high budding is a
process related to EMT. Our results of decreased E-
cadherin expression in tumour buds support this model
and are consistent with previous studies [3,16].
The studies on α6β4 in pre-clinical models of CRC
demonstrate a dualistic role for ITGB4: It is important
in hemidesmosome formation and cohesive function of
the epithelium, yet it has a migration- and invasion-
promoting function in association with the actin cyto-
skeleton and oncogenic signalling [36,37]. However,
no studies have quantitatively investigated the pheno-
typic changes associated with the transformation of
intact colorectal epithelium to high-grade tumour bud-
ding and especially analysed this in relation to ITGB4-
and EMT-associated epithelial marker expression
(e.g. E-cadherin, ZO-1). Nor have the current studies
properly addressed the association between ITGB4
expression and localisation and clinical outcomes in
CRC. One study investigated the association with
CRC patient survival but on a relatively small cohort
of 68 patients [23], concluding that higher ITGB4
expression is associated with cancer tissue and predicts
shorter OS. In general, the reports on ITGB4 expres-
sion in CRC have been controversial. Falcioni and
others (1994) [22] demonstrated that cell clusters sur-
rounded by stromal cells in poorly differentiated carci-
nomas showed elevated levels of ITGB4 expression.
In contrast, two other studies suggested decreased
levels of ITGB4 expression in colon cancer compared
with benign tissue [38,39]. Our results demonstrate
that the total expression levels of not only E-cadherin
but also of ITGB4 are, in fact, lower in cancer com-
pared to normal epithelium (adjacent to the tumour).
Furthermore, we show that both markers are weaker in
tumour buds than in the rest of the tumour epithelium
as measured in almost 40 000 epithelial clusters. The
stronger overall expression of ITGB4 in non-bud epi-
thelium is reflective of the strong ITGB4 in the basal
cell contacts and basal membrane of the more intact
epithelial clusters. ITGB4 expression levels alone in
epithelial clusters or within tumour buds did not pre-
dict survival. Importantly, however, we demonstrate
that, in a subpopulation of stage II patients, a high
number of ITGB4-high buds (≥25 buds) confers a sig-
nificantly elevated risk of aggressive disease. Our
results highlight the complex heterogeneous nature of
ITGB4 expression, which can be elaborately studied
using digital multiplexed marker analysis of combined
object intensity, structure (size), localisation, and
quantity (bud count).
We observed clear ITGB4 expression and localisa-
tion changes from basal cell–cell contacts in the
benign epithelium to diffuse cytoplasmic localisation
in the budding tumour cells. This was associated with
a significant reduction of ITGB4–E-cadherin co-locali-
sation, when measured across all the epithelial non-
bud clusters and buds. This phenotypic switch is in
line with the suggested conditional pro-invasion and
oncogenic signalling role of the α6β4 integrin hetero-
dimer [40]. Larjava at el. [41] already demonstrated in
1993 that, during wound healing of human mucosal
keratinocytes, ITGB4 changes its basal layer expres-
sion to a more cytoplasmic localisation. Similarly, in a
2D wound-healing experiment of colon epithelial cells,
ITGB4 localisation was changed from basal hemides-
mosomal plaques to protruding actin lamellae [42].
This phenotypic switch, which was later shown to be
linked with ITGB4 cytoplasmic tail phosphorylation,
dissociation from cytokeratin filaments, and hemides-
mosome disassembly, is also known to be associated
with oncogenic receptor–tyrosine kinase signalling
[37,40]. It is very possible that ITGB4 in tumour buds
binds to its ligand, laminin-γ2, which is a known tran-
scriptional target of β-catenin [43] and which has been
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shown to be more abundantly expressed at the inva-
sive front and to be associated with tumour budding
and with poor survival in pT3 CRC [24]. Interestingly,
α6β4 integrin is also associated with the tyrosine–
kinase receptor MET, which also shows higher expres-
sion at the invasive front areas with higher budding
grade [13]. In the future, our quantitative mIHC-based
phenotypic profiling of epithelial clusters and buds
will be instrumental in investigating the spatial inter-
play of ITGB4 with MET, laminin-γ2, and β-catenin
signalling in CRC tissue.
In summary, our study characterises the nature of
EMT-associated epithelial marker expression in epithe-
lial clusters and tumour buds and demonstrates the
power of our multiplex imaging in phenotypic profil-
ing of CRC. Our study shows that combined marker
intensity and marker-assisted morphology analysis
uncovers a subpopulation of tumours with a highly
aggressive epithelial phenotype of prognostic signifi-
cance. Importantly, the results provide evidence for
the translation of existing pre-clinical data into a clini-
cal setting, whereby the ITGB4 localisation shift from
basal cell–cell contacts in intact epithelium to the cyto-
plasm of invading cells is a phenotypic switch to more
aggressive stage II CRC.
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SUPPLEMENTARY MATERIAL ONLINE
Figure S1. Survival analysis of tumour budding from H&E-stained whole sections assessed by visual scoring according to ITBCC (2016) guide-
lines
Figure S2. Combination of C-11 and AE1/3 Pan-cytokeratin antibody clones improves the coverage of epithelial cell segmentation
Figure S3. Epithelial segmentation for the analysis of total epithelial buds and ITGB4-high buds and tight junctions
Figure S4. Nuclear count distribution in total buds and ITGB4-high buds
Table S1. Univariate and multivariate Cox regression analysis (DSS) for visually assessed tumour budding (two-tier) and for clinicopathological
variables
Table S2. Clinicopathological variables and their association with visually assessed H&E whole-section tumour budding and DSS using three-tier
patient grouping
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Table S3. Univariate Cox regression analysis (DSS) of digitally assessed epithelial marker expression levels in clusters and total buds of normal
epithelium, centre, and front TMA cores
Table S4. Clinicopathological variables of the validation cohort
Table S5. Univariate and multivariate Cox regression analysis (DSS) for digitally assessed ITGB4-high bud count and for clinicopathological vari-
ables used in the validation cohort
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